glp-1 inhibitor America's Poison Centers GLP-1-based therapies for type 2

The approval came as a consequence of the findings of phase 3a research published in the New England Journal of Medicine

It is not recommended for patients already experiencing gastrointestinal symptoms like bloating and nausea due to the potential aggravation of these symptoms

[Crossref] [PubMed] Gelaye B, Sacco S, Brown WJ, et al

doi: 10.3389/fphar.2023.1303844 Received 28 September 2023 Accepted 30 November 2023 Published 11 December 2023 Volume 14 - 2023 Edited by Alessio Squassina, University of Cagliari, Italy Reviewed by Michele Mazzanti, University of Milan, Italy Yashmin Choudhury, Assam University, India Updates Copyright 2023 Greco, Coperchini, Croce, Magri, Teliti and Rotondi

Some patients on higher doses may face additional cost variability

10.1056/NEJMoa2107519